<DOC>
	<DOCNO>NCT02523924</DOCNO>
	<brief_summary>This pilot study aim investigate diagnostic utility 18F-DCFPyL , novel low-molecular weight PSMA PET/CT image agent , men elevate PSA follow radical prostatectomy .</brief_summary>
	<brief_title>Pilot Study 18F-DCFPyL PET/CT Evaluation Men With Elevated PSA Following Radical Prostatectomy</brief_title>
	<detailed_description>18F-DCFPyL novel low-molecular weight PSMA imaging agent . A recent study patient metastatic prostate cancer find PSMA PET/CT identify site disease conventional imaging CT , MRI bone scan . In study aim investigate 18F-DCFPyL PET/CT patient elevate PSA follow radical prostatectomy . During course study , patient undergo two 18F-DCPyL PET/CT scan . The first scan take place within 45 day stag imaging second take place follow six month standard care therapy .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Age ≥18 year History adenocarcinoma prostate treat radical prostatectomy Serum PSA level ≥0.2 ng/mL least 45 day prior study enrollment Completed stag evaluation bone scan well CT MRI abdomen pelvis least 45 day prior study enrollment Intention enroll blind therapeutic clinical trial History malignancy diagnose within last three year ( exception squamous cell basal cell carcinoma skin )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>